Pre-exposure prophylaxis clinical trials of a 3-dose regimen of Verorab® followed by a booster dose at 1 year in adults and children achieved an adequate immune response.1 Of those who had a booster ...
Ensitrelavir significantly reduced the likelihood of developing symptomatic COVID-19 following household exposure compared with placebo. Treatment with ensitrelvir was found to prevent symptomatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback